Impact of the American College of Cardiology/American Heart Association Cholesterol Guidelines on Statin Eligibility Among Human Immunodeficiency Virus-Infected Individuals | Zendy

Mosepele Mosepele | Zendy; Susan Regan | Zendy; Joseph M. Massaro | Zendy; James B. Meigs | Zendy; Markella V. Zanni | Zendy; Ralph B. D’Agostino | Zendy; Steven Grinspoon | Zendy; Virginia A. Triant | Zendy

Open Access

Impact of the American College of Cardiology/American Heart Association Cholesterol Guidelines on Statin Eligibility Among Human Immunodeficiency Virus-Infected Individuals

Author(s) -

Mosepele Mosepele,

Susan Regan,

Joseph M. Massaro,

James B. Meigs,

Markella V. Zanni,

Ralph B. D’Agostino,

Steven Grinspoon,

Virginia A. Triant

Publication year - 2018

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofy326

Subject(s) - medicine , statin , medical prescription , cohort , physical therapy , pharmacology

In an HIV clinical care cohort, the ACC/AHA cholesterol guidelines recommend a higher proportion of patients for statin therapy and identify an increased proportion of patients with a CVD event compared with ATPIII. However, 40% of patients with a CVD event would not have been recommended for statin therapy by ACC/AHA, compared with 29% for controls. This gap in identification of patients infected with HIV at high CVD risk underscores the need for HIV-specific cardiovascular prevention strategies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research